Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment

Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells

(2015) Genevieve L. Weber et al.   Oncotarget

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

(2014) Claudia Fumarola et al.   BIOCHEMICAL PHARMACOLOGY

Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors

(2014) Lydia W.T. Cheung et al.   CANCER CELL

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity

(2014) Oliver Ou et al.   CANCER LETTERS

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin

(2014) Katherine A. Hoadley et al.   CELL

Estrogen Receptor and Receptor Tyrosine Kinase Signaling: Use of Combinatorial Hormone and Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2–Targeted Therapies for Breast Cancer

(2014) Daniel J. Zabransky et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

Challenges in the clinical development of PI3K inhibitors

(2013) Cristian Massacesi et al.   Annals of the New York Academy of Sciences

PIK3R1 underexpression is an independent prognostic marker in breast cancer

(2013) Magdalena Cizkova et al.   BMC CANCER

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

(2013) Helen J. Mackay et al.   CANCER

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

(2013) B. Weigelt et al.   CLINICAL CANCER RESEARCH

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

(2013) Jing Li et al.   Journal of Translational Medicine

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Pan-cancer patterns of somatic copy number alteration

(2013) Travis I Zack et al.   NATURE GENETICS

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

(2013) Jiri Polivka et al.   PHARMACOLOGY & THERAPEUTICS

Targeting PI3K in Cancer: Any Good News?

(2013) Miriam Martini et al.   Frontiers in Oncology

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

(2012) F. Janku et al.   CANCER RESEARCH

Targeting mTOR Pathways in Human Malignancies

(2012) Angelica Fasolo et al.   CURRENT PHARMACEUTICAL DESIGN

An emerging toolkit for targeted cancer therapies

(2012) G. B. Mills   GENOME RESEARCH

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

(2012) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

Recurrent R-spondin fusions in colon cancer

(2012) Somasekar Seshagiri et al.   NATURE

Somatic Mutations of PIK3R1 Promote Gliomagenesis

(2012) Steven N. Quayle et al.   PLoS One

Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent

(2012) Jing Ni et al.   Cancer Discovery

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia

(2012) Ines M. Macias-Perez et al.   Current Hematologic Malignancy Reports

HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer

(2011) E. A. Stronach et al.   CANCER RESEARCH

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

(2011) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

(2011) Vienna Ludovini et al.   Journal of Thoracic Oncology

Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism

(2011) Xuxiao Zhang et al.   MOLECULAR CELL

Targeted therapies: how personal should we go?

(2011) Miriam Martini et al.   Nature Reviews Clinical Oncology

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability

(2011) Lydia W.T. Cheung et al.   Cancer Discovery

Nuclear β-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells

(2010) Masahiro Uchino et al.   BMC CANCER

Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors

(2010) K. A. Edgar et al.   CANCER RESEARCH

The Phosphoinositide 3-Kinase Regulatory Subunit p85  Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling

(2010) C. M. Taniguchi et al.   CANCER RESEARCH

Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

(2010) J A DiMasi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Akt inhibitors in clinical development for the treatment of cancer

(2010) Sumanta Kumar Pal et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Subtle variations in Pten dose determine cancer susceptibility

(2010) Andrea Alimonti et al.   NATURE GENETICS

Cancer-derived mutations in the regulatory subunit p85  of phosphoinositide 3-kinase function through the catalytic subunit p110 

(2010) M. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase

(2010) R. B. Chagpar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation

(2009) Bijay S. Jaiswal et al.   CANCER CELL

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

(2009) Kathryn Balmanno et al.   INTERNATIONAL JOURNAL OF CANCER

p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex

(2009) R. Rabinovsky et al.   MOLECULAR AND CELLULAR BIOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110  and are disrupted in oncogenic p85 mutants

(2009) H. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt

(2008) X Yang et al.   BRITISH JOURNAL OF CANCER

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

(2008) N. T. Ihle et al.   CANCER RESEARCH

Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells

(2008) R. C-Y. Hui et al.   MOLECULAR CANCER THERAPEUTICS

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

The p110  isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110 

(2008) J. Guillermet-Guibert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA